SEC Form 4 · accession 0001596771-15-000054
Diplomat Pharmacy, Inc. · DPLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary W Kadlec
Officer — President · Director
Period of report
Jul 1, 2015
Accepted (ET)
Jul 6, 2015 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610092
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2015 | M | 30,000 | $4.28 | A | 30,000 | D | |
| Common StockF1,F2 | Jul 1, 2015 | S | 10,600 | $45.84 | D | 19,400 | D | |
| Common StockF1,F3 | Jul 1, 2015 | S | 19,400 | $45.21 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option to Acquire Common StockF4 | $4.28 | Jul 1, 2015 | M | 30,000 | D | — | Sep 1, 2022 | Common Stock | 30,000 | 324,658 | D |
Explanation of responses
- F1The sale was effected pursuant to a 10b5-1 trading plan initially adopted by the reporting person on June 24, 2015. The plan provides for monthly sales of 30,000 shares of common stock at the market price. Shares that are not sold in a particular month will be available for sale in subsequent months under the plan. A maximum of 150,000 shares remain available for sale under the plan, which is set to expire on December 31, 2015.
- F2The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $45.52 to $46.15 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
- F3The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $44.80 to $45.51 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
- F4The options were granted on 9/1/2012. The options began to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years. 50% of the options are currently vested and exercisable.